STAT3 and glioblastoma: Since STAT3 signaling is also necessary for maintaining normal stem cell self-renewal and immune cell activation, direct targeting of STAT3 itself is not clinically feasible; however, targeting STAT3 downstream genes presents a new alternative for eliminating GSCs to improve GBM treatment.